Sacubitril–valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction

Figures

• 

  Figure 1. Hazard and survival curves according to hypertension category. (A) Primary outcome. (B) Total heart failure hospitalizations. (C) Cardiovascular death, total heart failure hospitalizations, strokes, and myocardial infarctions. (D) Cardiovascular death. BP, blood pressure; CV, cardiovascular; HF, heart failure; MI, myocardial infarction.

• 

  Figure 2. Change in systolic blood pressure in patients with controlled blood pressure, ‘non-resistant’, ‘apparent resistant’, and ‘apparent mineralocorticoid receptor antagonist-resistant’ hypertension. Week −2 = end of the open run-in period of treatment with valsartan 80 mg twice daily and Week 0 = end of the open run-in period of treatment with sacubitril–valsartan 49/51 mg, Thereafter, patients randomized to double-blind treatment with valsartan 160 mg twice daily or sacubitril–valsartan 97/103 mg twice daily. Models include systolic blood pressure at the end of the valsartan run-in, age, sex, body mass index, cigarette smoking, and region, as well as systolic blood pressure at all other time points up to Week 16 and an interaction term between treatment and time. MRA, mineralocorticoid receptor antagonist.